{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:40:53Z","timestamp":1793882453295,"version":"4.7.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesalamine (5-aminosalicylic acid, [5-ASA]) is the first-line therapeutic agent in mild-to-moderate ulcerative colitis (UC). The continuous use of 5-ASA involves costs, adverse effects, and delayed treatment escalation. In certain circumstances, such as in patients with Crohn disease (CD) or patients escalated to advanced therapies, discontinuation of 5-ASA may be feasible. However, the implications of withdrawal on disease outcomes remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We sought to assess the relative risk (RR) of relapse in patients with quiescent UC or CD who discontinue 5-ASA compared with those who maintain treatment with 5-ASA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A search of 5 databases was conducted from inception until July 2024. Eligible studies were selected and subjected to quality assessment. The studies were categorized into 6 clinically relevant cohorts, and the RR of relapse was analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 7203 studies were identified, with 29 meeting inclusion criteria. The discontinuation of oral 5-ASA monotherapy was associated with a 60% increase in the risk of relapse in patients with UC (relative risk, 1.60; 95% C, 1.25-2.05; Grading of Recommendations Assessment, Development, and Evaluation [GRADE] level of certainty, low). The withdrawal of rectal 5-ASA resulted in a RR of relapse of 2.03 (95% CI, 1.58-2.61; GRADE level of certainty, moderate). In contrast, in patients receiving immunomodulators and\/or biologics, the cessation of 5-ASA was not associated with an increased risk of relapse (very low and low GRADE level of certainty, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The discontinuation of oral or rectal 5-ASA monotherapy in patients with UC is associated with an increased risk of relapse. The data for discontinuation of 5-ASA in patients with UC or CD who are on immunomodulators and\/or biologics is marginal for a meta-analysis; considering this limitation, these patients do not seem to have an increased risk of relapse upon discontinuation of 5-ASA, suggesting that monitored withdrawal may be a viable strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf277","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:46:36Z","timestamp":1761133596000},"page":"661-676","source":"Crossref","is-referenced-by-count":2,"title":["The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5642-8069","authenticated-orcid":false,"given":"Arteen","family":"Arzivian","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Inflammatory Bowel Disease Center , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary , Calgary, AB,","place":["Canada"]},{"name":"Department of Community Health Sciences, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Kerkham","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Nepean Hospital , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-4205","authenticated-orcid":false,"given":"Yvonne","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Macquarie University , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert W","family":"Leong","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2026040214063127500_izaf277-B1","doi-asserted-by":"crossref","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026040214063127500_izaf277-B2","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"2026040214063127500_izaf277-B3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA technical review on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology"},{"key":"2026040214063127500_izaf277-B4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2026040214063127500_izaf277-B5","doi-asserted-by":"crossref","first-page":"e0227914","DOI":"10.1371\/journal.pone.0227914","article-title":"Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"15","author":"Armuzzi","year":"2020","journal-title":"PLoS One"},{"key":"2026040214063127500_izaf277-B6","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.3748\/wjg.v23.i16.2995","article-title":"Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians\u2019 practice","volume":"23","author":"Ben-Horin","year":"2017","journal-title":"WJG"},{"key":"2026040214063127500_izaf277-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026040214063127500_izaf277-B9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ibd\/izaa127","article-title":"Trends of 5-aminosalicylate medication use in patients with Crohn disease","volume":"27","author":"Noureldin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063127500_izaf277-B11","first-page":"500","article-title":"The use of 5-aminosalicylates in Crohn\u2019s disease: a retrospective study using the UK Clinical Practice Research Datalink","volume":"33","author":"Hart","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"2026040214063127500_izaf277-B12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjv117","article-title":"Health care cost analysis in a population-based inception cohort of inflammatory bowel disease patients in the first year of diagnosis","volume":"9","author":"Niewiadomski","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2026040214063127500_izaf277-B13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.14309\/ajg.0000000000000847","article-title":"Cost-effectiveness of 5-aminosalicylate therapy in combination with biologics or tofacitinib in the treatment of ulcerative colitis","volume":"116","author":"Shaffer","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"key":"2026040214063127500_izaf277-B16","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/MIB.0000000000000076","article-title":"Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis","volume":"20","author":"Lichtenstein","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063127500_izaf277-B17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/apt.14023","article-title":"Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease","volume":"45","author":"Bonovas","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000518865","article-title":"5-Aminosalicylic acid chemoprevention in inflammatory bowel diseases: is it necessary in the age of biologics and small molecules?","volume":"7","author":"Herfarth","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"2026040214063127500_izaf277-B20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/ajg.2011.50","article-title":"5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study","volume":"106","author":"Bernstein","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026040214063127500_izaf277-B22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/apt.15771","article-title":"withdrawal of 5-aminosalicylates in inflammatory bowel disease","volume":"52","author":"Chapman","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"2026040214063127500_izaf277-B24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026040214063127500_izaf277-B25","author":"Wells"},{"key":"2026040214063127500_izaf277-B26","author":"Bro\u017cek"},{"key":"2026040214063127500_izaf277-B27","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"key":"2026040214063127500_izaf277-B28","volume-title":"RStudio: Integrated Development for R","author":"RStudio Team","year":"2015"},{"key":"2026040214063127500_izaf277-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Soft"},{"key":"2026040214063127500_izaf277-B30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00365521.1973.12096672","article-title":"The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment: a double-blind trial on patients asymptomatic for one year","volume":"8","author":"Riis","year":"1973","journal-title":"Scand J Gastroenterol"},{"key":"2026040214063127500_izaf277-B31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/gut.14.12.923","article-title":"A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)","volume":"14","author":"Dissanayake","year":"1973","journal-title":"Gut"},{"key":"2026040214063127500_izaf277-B32","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0016-5085(86)90882-6","article-title":"Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse-prevention properties","volume":"90","author":"Sandberg-Gertz\u00e9n","year":"1986","journal-title":"Gastroenterology"},{"key":"2026040214063127500_izaf277-B33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7326\/0003-4819-124-2-199601150-00003","article-title":"An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial","volume":"124","author":"Hanauer","year":"1996","journal-title":"Ann Intern Med"},{"key":"2026040214063127500_izaf277-B34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2036.1999.00473.x","article-title":"Is maintenance therapy always necessary for patients with ulcerative colitis in remission?","volume":"13","author":"Ardizzone","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B35","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jgh.15838","article-title":"increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study","volume":"37","author":"Mak","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B36","first-page":"269","article-title":"Stopping 5-aminosalicyclic acid in patients with long-standing inactive ulcerative colitis is not associated with an increased risk of relapse: results from a multi-center, double-blind, randomized, placebo-controlled trial","volume":"10","author":"Ng","year":"2022","journal-title":"Moderated Posters. United European Gastroenterol J"},{"key":"2026040214063127500_izaf277-B37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis","volume":"94","author":"Biddle","year":"1988","journal-title":"Gastroenterology"},{"key":"2026040214063127500_izaf277-B38","first-page":"1079","article-title":"5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial","volume":"85","author":"D\u2019Arienzo","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B39","first-page":"A736","article-title":"The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative-colitis","volume":"106","author":"Miner","year":"1994","journal-title":"Gastroenterology"},{"key":"2026040214063127500_izaf277-B40","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","author":"d\u2018Albasio","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.42.2.195","article-title":"Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study","volume":"42","author":"Marteau","year":"1998","journal-title":"Gut"},{"key":"2026040214063127500_izaf277-B42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial","volume":"93","author":"d\u2019Albasio","year":"1998","journal-title":"American J Gastroenterol"},{"key":"2026040214063127500_izaf277-B43","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1572-0241.2000.02185.x","article-title":"Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis","volume":"95","author":"Hanauer","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00365520310008133","article-title":"Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis","volume":"39","author":"Piodi","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"2026040214063127500_izaf277-B45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ibd.20158","article-title":"Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study","volume":"13","author":"Yokoyama","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063127500_izaf277-B46","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/00042737-200111000-00006","article-title":"Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy","volume":"13","author":"Campbell","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B47","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1572-0241.2004.11481.x","article-title":"A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis","volume":"99","author":"Mantzaris","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/apt.15876","article-title":"benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy","volume":"52","author":"Singh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B49","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/apt.16518","article-title":"Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study","volume":"54","author":"Bernstein","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MEG.0b013e3282f16d50","article-title":"Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome","volume":"20","author":"Shah","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B51","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s10620-021-07301-x","article-title":"No benefit of continuing 5-aminosalicylates in patients with Crohn\u2019s disease treated with anti-metabolite therapy","volume":"67","author":"Picetti","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026040214063127500_izaf277-B52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41395-018-0144-2","article-title":"No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026040214063127500_izaf277-B53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","article-title":"Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts","volume":"68","author":"Ungaro","year":"2019","journal-title":"Gut"},{"key":"2026040214063127500_izaf277-B54","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.cgh.2018.11.062","article-title":"Concomitant use of aminosalicylates is not associated with improved outcomes in patients with ulcerative colitis escalated to vedolizumab","volume":"17","author":"Ma","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ygh2.391","article-title":"Aminosalicylate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy","volume":"2","author":"Nicolaides","year":"2020","journal-title":"GastroHep"},{"key":"2026040214063127500_izaf277-B56","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.cgh.2019.08.012","article-title":"Stopping mesalamine therapy in patients with Crohn\u2019s disease starting biologic therapy does not increase risk of adverse outcomes","volume":"18","author":"Ungaro","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063127500_izaf277-B57","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00384-019-03368-1","article-title":"Comparison of outcomes of continuation\/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease","volume":"34","author":"Choi","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"2026040214063127500_izaf277-B58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.18102","article-title":"Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study","volume":"60","author":"Seo","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B59","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apt.17419","article-title":"5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn\u2019s disease\u2014A nationwide cohort study","volume":"57","author":"Atia","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.crohns.2010.06.002","article-title":"5-Aminosalicylic acid dependency in Crohn\u2019s disease: a Danish Crohn Colitis Database study","volume":"4","author":"Duricova","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2026040214063127500_izaf277-B61","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/apt.13973","article-title":"Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn\u2019s disease","volume":"45","author":"Jairath","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063127500_izaf277-B62","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360."},{"key":"2026040214063127500_izaf277-B63","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/661\/65729667\/izaf277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/661\/65729667\/izaf277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:06:45Z","timestamp":1775153205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/4\/661\/8363957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf277","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,3]]}}}